1. ALLA AKTIER
  2. NYHETER
  3. NEWBURY PHARMACEUTICALS

Newbury Pharmaceuticals

Nyheter Newbury Pharmaceuticals Nyheter alla bolag

Newbury Pharmaceuticals publishes its annual report for 2023/2024

MARKN.

Newbury Pharmaceuticals AB has published its annual report for the 2023/2024 financial year.

The annual report for 2023/2024 is available to download on the company's website www.newburypharma.com/investors/. The Annual General Meeting will be held on Wednesday, January 15, 2025.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Newbury Pharmaceuticals Årsredovisning September 2023 Augusti 2024

Datum 2024-12-11, kl 19:30
Källa MFN
Bifogade filer
Newbury Pharmaceuticals Årsredovisning September 2023 Augusti 2024
Affiliate
200 kr till alla nya kunder! Just nu får alla nya kunder på Nordnet 200 kronor insatta i fonden Nordnet One Offensiv. Erbjudandet gäller mellan 1:e och 30:e september!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet